Business Context and Reporting Period
This Form 8-K Current Report was filed by Disc Medicine, Inc. (Nasdaq: IRON) on July 9, 2025. The report details the election of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change reported is the election of Nadim Ahmed as a director, effective July 14, 2025. Mr. Ahmed is designated as a Class I director serving until the 2027 Annual Meeting of Stockholders.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or general management commentary regarding business operations. It details specific compensatory arrangements for the new director:
- Cash Compensation: $40,000 annually ($10,000 per quarter) plus reimbursement for reasonable out-of-pocket expenses.
- Equity Grant: A non-statutory stock option to purchase 20,000 shares of common stock.
- Vesting Schedule: The option vests over three years, with one-third vesting on the first anniversary and the remainder in equal monthly installments over the subsequent two years. Vesting ceases upon resignation unless the Board determines otherwise.
- Indemnification: Mr. Ahmed will enter into an indemnification agreement covering expenses, judgments, fines, and settlement amounts related to his service as a director.
Investor Verification Checklist
- Verify the closing price of IRON common stock on July 14, 2025, to determine the exercise price of the 20,000 share option granted to Nadim Ahmed.
- Review the full text of the Indemnification Agreement referenced in Exhibit 10.3 of the December 29, 2022, Form 8-K.
- Confirm the total number of outstanding shares and the impact of this new option grant on potential dilution.
- Check for any subsequent filings regarding Mr. Ahmed's background or potential conflicts of interest not disclosed in this summary.